Gene therapy for ischemic heart disease

Area of Science:

• Cardiovascular Research
• Gene Therapy
• Molecular Cardiology

Background:

• Coronary artery disease (CAD) remains a leading cause of death, with 30% of patients developing heart failure post-treatment.
• Ischemic heart disease involves adverse cardiac remodeling, including cardiomyocyte hypertrophy, fibrosis, and reduced capillary density.

Purpose of the Study:

• To review current vector systems for gene therapy targeting angiogenesis and contractility.
• To explore the potential of microRNA (miRNA) modulation for enhancing survival and pro-angiogenic genes.
• To discuss optimal gene therapy application routes for localized cardiac treatment.

Main Methods:

• Assessment of existing vector systems for cardiac gene delivery.
• Review of microRNA (miRNA) targets involved in angiogenesis and cardiac contractility.
• Discussion of regional versus systemic gene therapy administration.

Main Results:

• MicroRNA antagonists demonstrate selective uptake and prolonged presence in ischemic myocardial tissue, suggesting efficacy for acute myocardial infarction.
• Regional intravenous application of adeno-associated virus (AAV) vectors with vascular growth factors promotes angiogenesis, vessel maturation, and collateral growth.
• Combination therapy with genes enhancing cardiac contractility may further improve outcomes.

Conclusions:

• MicroRNAs represent a promising avenue for cardiac gene therapy, particularly for acute myocardial infarction.
• Regional delivery of AAV vectors carrying vascular growth factors and contractility-enhancing genes is a viable strategy for ischemic heart disease.
• The selective absorption and sustained presence of miRNA antagonists in ischemic tissue support their therapeutic potential.